Taxane and Carboplatin + Short-term Sintilimab
ApprovedRecruiting 0 watching 0 views this week🔥 Hot
84
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Triple-negative Breast Cancer
Conditions
Triple-negative Breast Cancer
Trial Timeline
Jul 1, 2023 → Dec 31, 2034
NCT ID
NCT05843292About Taxane and Carboplatin + Short-term Sintilimab
Taxane and Carboplatin + Short-term Sintilimab is a approved stage product being developed by Innovent Biologics for Triple-negative Breast Cancer. The current trial status is recruiting. This product is registered under clinical trial identifier NCT05843292. Target conditions include Triple-negative Breast Cancer.
Hype Score Breakdown
Clinical
30
Activity
20
Company
9
Novelty
10
Community
12
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05843292 | Approved | Recruiting |
Competing Products
20 competing products in Triple-negative Breast Cancer